Lenvima 10mg Capsule

Most side effects of Lenvima 10mg Capsule do not require medical attention as they may disappear as your body adjusts to the medicine. If these side effects worsen, consult your doctor immediately. Serious side effects may include high blood pressure, heart problems, bleeding, liver or kidney issues, severe digestive symptoms, seizures, vision changes, or confusion. In rare cases, these could signal posterior reversible encephalopathy syndrome (PRES), a brain condition. Common side effects are as follows:

• Cough  
• Nausea 
• Sore throat 
• Vomiting  
• Weakness  
• Dizziness
• Fever
• Decrease in white blood cell count
• Sleepiness
• Swelling
• Respiratory disorder
• Bleeding gums
• Blood clots
• Decreased calcium level in the blood
• High blood pressure
• Diarrhea
  
• Low appetite
• Weight loss
• Joint and muscle pain

• Your doctor will determine your dose based on your medical condition and requirements. 
• Take Lenvima Capsule as prescribed by your doctor.
• Do not chew or open the capsule.
• Take this medicine with or without food.

• Lenvima 10mg Capsule contains Lenvatinib, which is a receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1, VEGFR2, and VEGFR3.
• Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression, in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET.
• After the oral administration, the effect of this medicine can be observed in 1 to 4 hours. 
  

• ​If you miss a dose of Lenvima 10mg Capsule, make sure to contact your healthcare professional before taking the next dose.
• Do not try to cope with the missed dose by doubling the strength of your next dose.
  

• Kang, W. et al. (2025). Real‑world safety and effectiveness of LENVIMA® (lenvatinib) in unresectable hepatocellular carcinoma in Korea: post‑marketing study. International Journal of Clinical Practice - https://pubmed.ncbi.nlm.nih.gov/39320906/
  
• Chiang, C.-H., Yang, J.-D., Liu, W.-L., Chang, F.-Y., Yang, C.-J., Hsu, K.-W., Chiang, I.-T., & Hsu, F.-T. (2025). Mechanistic insights of lenvatinib: Enhancing cisplatin sensitivity, inducing apoptosis, and suppressing metastasis in bladder cancer cells through EGFR/ERK/P38/NF‑κB signaling inactivation - https://pubmed.ncbi.nlm.nih.gov/39955573/
  
• Fan , F.M et al. (2024). New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma. Drug Discovery Today, 29(8), 104069 - https://pubmed.ncbi.nlm.nih.gov/38936692/ - https://pubmed.ncbi.nlm.nih.gov/38936692/
  
• Locati, L. D., et al. (2024). Study confirms Lenvima’s benefits in radioiodine‑refractory differentiated thyroid cancer: real‑world outcomes from Europe and Canada. Annals of Oncology.
  Tao, M., Han, J., Shi, J., Liao, H., Wen, K., Wang, W., Mui, S., Li, H., Yan, Y., & Xiao, Z. (2023). Application and resistance mechanisms of lenvatinib in patients with advanced hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 10, 1069–1083 - https://pubmed.ncbi.nlm.nih.gov/37457652/